Dolutegravir Expanded Access Study (DEAP)
Recruitment status was Available
ING114916 is an open-label, multi-center, expanded access (EAP) study
|Study Type:||Expanded Access What is Expanded Access?|
|Official Title:||A GSK1349572 Open Label Protocol for HIV Infected, Adult Patients With Integrase Resistance|
|Study Start Date:||February 2012|
ING114916 is an open-label, multi-center EAP to allow access to patients with HIV-1 infection who have documented raltegravir or elvitegravir resistance, have limited treatment options and require dolutegravir to construct a viable anti-retroviral regimen for therapy. Patients must not be eligible for another ongoing dolutegravir clinical trial in order to participate in this EAP.
The duration of patient accrual into the study will extend until dolutegravir receives local (by country) regulatory approval.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01536873
|Contact: US GSK Clinical Trials Call Center||877-379-3718||GSKClinicalSupportHD@gsk.com|
|Study Director:||GSK Clinical Trials||ViiV Healthcare|